Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead.
暂无分享,去创建一个
[1] G. Rossi,et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. , 2005, Blood.
[2] S. Apte,et al. Egr-1 Mediates Extracellular Matrix-driven Transcription of Membrane Type 1 Matrix Metalloproteinase in Endothelium* , 1999, The Journal of Biological Chemistry.
[3] M. Hollenberg,et al. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. , 2001, The Biochemical journal.
[4] Stephen J. Weiss,et al. Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3 , 2000, The Journal of cell biology.
[5] J. Winer,et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.
[6] Kenji Nakamura,et al. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells , 2007, Journal of Cell Science.
[7] D. McDonald,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.
[8] Christopher M Overall,et al. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.
[9] J. Gutkind,et al. MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D* , 2007, Journal of Biological Chemistry.
[10] Bonnie F. Sloane,et al. Pericellular cathepsin B and malignant progression , 2003, Cancer and Metastasis Reviews.
[11] G. Davis,et al. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3 , 2006, The Journal of cell biology.
[12] B. Sumpio,et al. Transcription Factor Sp1 Phosphorylation Induced by Shear Stress Inhibits Membrane Type 1-Matrix Metalloproteinase Expression in Endothelium* , 2002, The Journal of Biological Chemistry.
[13] D. Gingras,et al. Src-dependent Phosphorylation of Membrane Type I Matrix Metalloproteinase on Cytoplasmic Tyrosine 573 , 2007, Journal of Biological Chemistry.
[14] D. Rifkin,et al. Proteolytic control of growth factor availability , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[15] J. Joyce,et al. Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.
[16] P. Carmeliet. Angiogenesis in health and disease , 2003, Nature Medicine.
[17] P. Quax,et al. Pericellular proteases in angiogenesis and vasculogenesis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[18] D. Pode,et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.
[19] T. Ohtsuka,et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity , 2007, Nature Neuroscience.
[20] D. Edwards,et al. Metalloproteinases and their inhibitors in tumor angiogenesis , 2005, International journal of cancer.
[21] M. Yáñez-Mó,et al. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. , 2005, Blood.
[22] R. Maehr,et al. Invariant Chain Controls the Activity of Extracellular Cathepsin L , 2002, The Journal of experimental medicine.
[23] A. Luttun,et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.
[24] J. Foidart,et al. Expression Pattern of Metalloproteinases and Tissue Inhibitors of Matrix-Metalloproteinases in Cycling Human Endometrium1 , 2003, Biology of reproduction.
[25] R. Raedt,et al. Endothelial Outgrowth Cells Are Not Derived From CD133+ Cells or CD45+ Hematopoietic Precursors , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[26] 小崎 直人. Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice , 2007 .
[27] Michael P Vitek,et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways , 2007, Proceedings of the National Academy of Sciences.
[28] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[29] J. Keiser,et al. Hepatocyte growth factor enhances MMP activity in human endothelial cells. , 2000, Biochemical and biophysical research communications.
[30] G. Murphy,et al. Identification of the Extracellular Matrix (ECM) Binding Motifs of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Effective Transfer to TIMP-1* , 2007, Journal of Biological Chemistry.
[31] V. V. van Hinsbergh,et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. , 2001, Blood.
[32] E. Chavakis,et al. Cathepsin L is required for endothelial progenitor cell–induced neovascularization , 2005, Nature Medicine.
[33] S. Itohara,et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.
[34] Motoharu Seiki,et al. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.
[35] J. Liao,et al. Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .
[36] Andrew J. Ewald,et al. Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.
[37] Noriko Ito,et al. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. , 2006, Molecular biology of the cell.
[38] James P. Quigley,et al. Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer , 2003, Cancer and Metastasis Reviews.
[39] Chiaki Takahashi,et al. RECK: A novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling , 2003, Cancer and Metastasis Reviews.
[40] Yasufumi Sato. Role of aminopeptidase in angiogenesis. , 2004, Biological & pharmaceutical bulletin.
[41] M. Luisa Iruela-Arispe,et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.
[42] W. Stetler-Stevenson,et al. Shp-1 Mediates the Antiproliferative Activity of Tissue Inhibitor of Metalloproteinase-2 in Human Microvascular Endothelial Cells* , 2006, Journal of Biological Chemistry.
[43] P. Polverini. Role of the macrophage in angiogenesis-dependent diseases. , 1997, EXS.
[44] D. Gingras,et al. Activation of the extracellular signal‐regulated protein kinase (ERK) cascade by membrane‐type‐1 matrix metalloproteinase (MT1‐MMP) , 2001, FEBS letters.
[45] T. Gridley. Notch signaling in vascular development and physiology , 2007, Development.
[46] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[47] F. Dignat-George,et al. High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors , 2006, Thrombosis and Haemostasis.
[48] M. Ratajczak,et al. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. , 2000, Experimental hematology.
[49] G. Ciliberto,et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.
[50] A. Strongin,et al. Centrosomal Pericentrin Is a Direct Cleavage Target of Membrane Type-1 Matrix Metalloproteinase in Humans but Not in Mice , 2005, Journal of Biological Chemistry.
[51] Fuquan Yang,et al. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. , 2005, Blood.
[52] G. Zheng,et al. Production of matrix metalloproteinase-9 by cord blood CD34+ cells and its role in migration , 2004, Annals of Hematology.
[53] Hiroshi Ohno,et al. Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity , 2001, The Journal of cell biology.
[54] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.
[55] R. W. Rauser,et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[56] Motoharu Seiki,et al. MT1‐MMP: A potent modifier of pericellular microenvironment , 2006, Journal of cellular physiology.
[57] G. Rossi,et al. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. , 2006, Cancer research.
[58] Xu-wen Liu,et al. Novel functions of TIMPs in cell signaling , 2006, Cancer and Metastasis Reviews.
[59] S. Dimmeler,et al. Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.
[60] L. Claesson‐Welsh,et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 , 2003, Nature Medicine.
[61] M. Reed,et al. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? , 2003, Journal of the National Cancer Institute.
[62] C. Overall,et al. TIMP Independence of Matrix Metalloproteinase (MMP)-2 Activation by Membrane Type 2 (MT2)-MMP Is Determined by Contributions of Both the MT2-MMP Catalytic and Hemopexin C Domains* , 2006, Journal of Biological Chemistry.
[63] P. ten Dijke,et al. Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.
[64] Neil D. Rawlings,et al. Handbook of proteolytic enzymes , 1998 .
[65] Hyun-Jai Cho,et al. Cytokines and Matrix Metalloproteinases Progenitor Cells and Late Outgrowth Endothelial Cells: the Role of Angiogenic Synergistic Neovascularization by Mixed Transplantation of Early Endothelial Synergistic Neovascularization by Mixed Transplantation of Early Endothelial Progenitor Cells and Late Ou , 2022 .
[66] P. Dijke,et al. Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.
[67] S. Rafii,et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9–mediated progenitor cell mobilization , 2005, The Journal of experimental medicine.
[68] C. Overall,et al. Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.
[69] M. Iruela-Arispe,et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2 , 2006, The EMBO journal.
[70] Ji Ming Wang,et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[71] P. Carmeliet,et al. uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.
[72] R. Kalluri. Basement membranes: structure, assembly and role in tumour angiogenesis , 2003, Nature reviews. Cancer.
[73] S. Groshen,et al. Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment , 2004, Cancer Research.
[74] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[75] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[76] C. Heeschen,et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.
[77] Jeffrey W. Smith,et al. Proteolysis of the Membrane Type-1 Matrix Metalloproteinase Prodomain , 2007, Journal of Biological Chemistry.
[78] Pieter Koolwijk,et al. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. , 2004, The Journal of clinical endocrinology and metabolism.
[79] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[80] B. Levkau,et al. ADAM15 is an adherens junction molecule whose surface expression can be driven by VE-cadherin. , 2002, Experimental cell research.
[81] T. Asahara,et al. Endothelial progenitor cells for postnatal vasculogenesis. , 2004, American journal of physiology. Cell physiology.
[82] G. Nickenig,et al. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[83] B. Bauvois. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? , 2004, Oncogene.
[84] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[85] M. Stack,et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion , 2007, Nature Cell Biology.
[86] Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003 .
[87] K. Gray,et al. Roles and regulation of membrane-associated serine proteases. , 2007, Biochemical Society transactions.
[88] D. Seals,et al. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. , 2003, Genes & development.
[89] Stefan Rose-John,et al. Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.
[90] H. Mori,et al. CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.
[91] V. V. van Hinsbergh,et al. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.
[92] R. Khokha,et al. TIMP-3 Deficiency Leads to Dilated Cardiomyopathy , 2004, Circulation.
[93] Pawan Kumar,et al. Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. , 2003, Blood.
[94] U. Weidle,et al. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. , 1999, The American journal of pathology.
[95] R. Williamson,et al. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. , 2003, Biochemical Society symposium.
[96] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[97] María Yáñez-Mó,et al. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. , 2003, Molecular biology of the cell.
[98] M. Yoder,et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. , 2007, Experimental hematology.
[99] F. Blasi,et al. Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor , 2002, Thrombosis and Haemostasis.
[100] M. Iruela-Arispe,et al. Thrombospondin modules and angiogenesis. , 2004, The international journal of biochemistry & cell biology.
[101] A Cumano,et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.
[102] K. Horiuchi,et al. Potential Role for ADAM15 in Pathological Neovascularization in Mice , 2003, Molecular and Cellular Biology.
[103] U. Sen,et al. Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)* , 2006, Journal of Biological Chemistry.
[104] J. Foidart,et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. , 2006, Cancer research.
[105] Antonio S. Tutor,et al. Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells. , 2007, Blood.
[106] Ronit Vogt Sionov,et al. CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.
[107] G. Weskamp,et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands , 2004, The Journal of cell biology.
[108] J. Couchman,et al. Palmitoylation at Cys574 is essential for MT1‐MMP to promote cell migration , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[109] C. Blobel,et al. Adam Meets Eph: An ADAM Substrate Recognition Module Acts as a Molecular Switch for Ephrin Cleavage In trans , 2005, Cell.
[110] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[111] A. Newby,et al. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.
[112] B. de Strooper,et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. , 2002, Human molecular genetics.
[113] Christopher M. Overall,et al. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.
[114] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[115] Lance C Bridges,et al. ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. , 2005, Current pharmaceutical design.
[116] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[117] S. Salzano,et al. The Cleavage of the Urokinase Receptor Regulates Its Multiple Functions* , 2002, The Journal of Biological Chemistry.
[118] Takanori Aoki,et al. Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.
[119] D. Edwards,et al. The ADAMTS metalloproteinases. , 2005, The Biochemical journal.
[120] T. Tahir,et al. Regulated Proteolytic Processing of Tie1 Modulates Ligand Responsiveness of the Receptor-tyrosine Kinase Tie2* , 2007, Journal of Biological Chemistry.
[121] J. Foidart,et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. , 2008, Biochimie.
[122] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[123] G. Murphy,et al. Delineating the Molecular Basis of the Inactivity of Tissue Inhibitor of Metalloproteinase-2 against Tumor Necrosis Factor-α-converting Enzyme* , 2004, Journal of Biological Chemistry.
[124] R. Sidman,et al. Impaired angiogenesis in aminopeptidase N-null mice , 2007, Proceedings of the National Academy of Sciences.
[125] Stephen J. Weiss,et al. MT1-MMP–dependent neovessel formation within the confines of the three-dimensional extracellular matrix , 2004, The Journal of cell biology.
[126] David A. Davis,et al. Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity , 2004 .